Karyopharm Therapeutics (KPTI)
(Delayed Data from NSDQ)
$1.03 USD
+0.02 (1.98%)
Updated Jun 12, 2024 04:00 PM ET
After-Market: $1.04 +0.01 (0.97%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Brokerage Reports
Karyopharm Therapeutics Inc. [KPTI]
Reports for Purchase
Showing records 261 - 280 ( 387 total )
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Karyopharm 3Q18 Results; Positive Selinexor Progress and Platform Updates
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Upgrading to OUTPERFORM: Expect Positive SADAL Data at ASH; Approval Next April
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Karyopharm Receives FDA Fast Track Designation for Selinexor in Relapsed DLBCL
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
UPDATED: ASH 2018 Abstract Roundup and Schedule for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
CORRECTED: ASH 2018 Abstract Roundup and Schedule for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Karyopharm to Present Data Including Phase 2b SADAL Top-line at ASH 2018
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Selinexor Granted Priority Review; PDUFA Date April 6, 2019
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Updates Positive Phase 2b STORM Data in MM at SOHO; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Karyopharm to Present Additional Phase 2b STORM Data at SOHO Meeting in September
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Uncertain Market Outlook for Sel makes this a Wait-and-See Story
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Karyopharm Reports 2Q18 Results; Rolling NDA Submission Complete
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Karyopharm Initiates Rolling NDA Submission for Selinexor; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Positive Selinexor STOMP Multiple Myeloma Data Update at EHA
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
KPTI Out-licenses Selinexor, Eltanexor, Verdinexor and KPT-9274 in China and Other Asia Countries
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Downgrading to NEUTRAL, Shares Fully Valued Here, in Our View
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D